AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. (AYTU) on May 24, 2022. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market. The report addresses a specific regulatory notice received from the Nasdaq Stock Market, LLC regarding the Company's stock price.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing status notification rather than financial performance data.
Material Changes and Events
- Nasdaq Non-Compliance Notice: On May 24, 2022, the Company received a notice from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of its common stock was below the minimum $1.00 per share requirement.
- Current Listing Status: The notice has no immediate effect on the listing; the stock continues to trade under the symbol "AYTU."
- Compliance Timeline: The Company has an initial 180-day period (until November 21, 2022) to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing bid price and consider available options if the price remains below $1.00. The Company may be eligible for an additional compliance period if it meets all other listing requirements and provides written notice of its intention to cure the deficiency, potentially through a reverse stock split. There is no assurance that the Company will regain compliance or that an appeal to a Nasdaq Hearings Panel would be successful if delisting occurs.
Key Facts for Investor Verification
- Verify the current closing bid price of AYTU stock to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding a potential reverse stock split to cure the deficiency.
- Track the 180-day compliance deadline ending November 21, 2022.
- Review subsequent filings for any updates on the Company's financial condition, as this 8-K does not contain financial statements.